Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 73

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016', provides in depth analysis on Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted pipeline therapeutics.

The report provides comprehensive information on the Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)

  • The report reviews Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) Overview 7
Therapeutics Development 8
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Products under Development by Stage of Development 8
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Products under Development by Therapy Area 9
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Products under Development by Indication 10
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Products under Development by Companies 14
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Companies Involved in Therapeutics Development 23
Angion Biomedica Corp. 23
Bristol-Myers Squibb Company 24
Galectin Therapeutics, Inc. 25
GlycoMimetics, Inc. 26
MandalMed, Inc. 27
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Drug Profiles 28
ANG-4021 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Drug to Inhibit Gal-3 for Oncology - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
G-XXX - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
GMCT-01 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
GMCT-04 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
GRMD-02 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
GRMD-03 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
GRMD-04 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
Small Molecule to Inhibit Galectin-3 for Fibrosis, Oncology and Cardiovascular Disease - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
TD-139 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
TFD-100 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Dormant Projects 57
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Discontinued Products 59
Galectin 3 (35 kDa Lectin or Carbohydrate Binding Protein 35 or Galactose Specific Lectin 3 or Galactoside Binding Protein or IgE Binding Protein or Laminin Binding Proteinor Mac 2 Antigen or LGALS3) - Featured News & Press Releases 60
Aug 25, 2016: Galectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical Trial 60
Aug 02, 2016: Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis 60
Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis 61
Jun 02, 2016: Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension 62
May 16, 2016: Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis 63
May 11, 2016: Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis 64
May 05, 2016: Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference 64
Feb 24, 2016: Galectin Therapeutics Receives U.S. Patent Allowance for GR-MD-02 to Treat Pulmonary Fibrosis 65
Jan 07, 2016: Galectin Therapeutics Posts "2015-2016, Progress and Possibilities" to Corporate Website 66
Nov 11, 2015: Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting 67
Oct 19, 2015: Galectin Therapeutics ‘GR-MD-02 to be Studied in Combination with Keytruda in Patients with Metastatic Melanoma 68
Sep 24, 2015: Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02 69
Sep 16, 2015: Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis 69
Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases 70
Aug 03, 2015: Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to use BreathID to Monitor Patients with Cirrhosis Associated with NASH 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 (Contd..1) 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Angion Biomedica Corp., H2 2016 23
Pipeline by Bristol-Myers Squibb Company, H2 2016 24
Pipeline by Galectin Therapeutics, Inc., H2 2016 25
Pipeline by GlycoMimetics, Inc., H2 2016 26
Pipeline by MandalMed, Inc., H2 2016 27
Dormant Projects, H2 2016 57
Dormant Projects (Contd..1), H2 2016 58
Discontinued Products, H2 2016 59

List of Figures

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 21
  • Biotechnology services Global Market Briefing 2017
    Published: 05-Dec-2016        Price: US 1000 Onwards        Pages: 35
    Biotechnology services market is engaged in usage of biological processes for industrial purpose. Establishments in this market are involved in providing contract based research, analyses and other services. The Biotechnology Services Global Market Briefing provides strategists, marketers and senior management with the critical information they need to assess the biotechnology services market. Reasons to Purchase • Get up to date information available on th......
  • Cartilage Repair/ Cartilage Regeneration Market by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), Region - Forecast to 2021
    Published: 05-Dec-2016        Price: US 5650 Onwards        Pages: 102
    The global cartilage repair/ cartilage regeneration market is projected to reach USD 779.8 million by 2021 from USD 414.6 million in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, the cartilage repair/ cartilage regeneration market is segmented on the basis of treatment modalities, application, and region. Factors such as Increase in obese population and rising incidence of sports injuries are the major factors driving the growth of cartil......
  • United States, EU, Japan, China, India and Southeast Asia Biosimulation Market Size, Status and Forecast 2021
    Published: 02-Dec-2016        Price: US 3300 Onwards        Pages: 94
    Notes: Production, means the output of Biosimulation Revenue, means the sales value of Biosimulation This report studies the global Biosimulation market, analyzes and researches the Biosimulation development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Certara - Simulation Plus - Dassault Systèmes - Schr?dinger - Advanced Chemistry D......
  • Global Protein Expression System Market Professional Survey Report 2016
    Published: 30-Nov-2016        Price: US 3500 Onwards        Pages: 106
    Notes: Production, means the output of Protein Expression System Revenue, means the sales value of Protein Expression System This report studies Protein Expression System in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production......
  • United States Medical Swab Market Report 2016
    Published: 29-Nov-2016        Price: US 3800 Onwards        Pages: 102
    Notes: Sales, means the sales volume of Medical Swab Revenue, means the sales value of Medical Swab This report studies sales (consumption) of Medical Swab in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Medical Wire & Equipment - Puritan Medical Products - F.L. Medical - Copan Split by product types, with sales, revenue, price, market share and gro......
  • Global Cell Counting Sales Market Report 2016
    Published: 29-Nov-2016        Price: US 4000 Onwards        Pages: 120
    Notes: Sales, means the sales volume of Cell Counting Revenue, means the sales value of Cell Counting This report studies sales (consumption) of Cell Counting in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Thermo Fisher Scientific - Merck - BD - Bio-Rad - Pe......
  • Immunohistochemistry Market by Product (Antibody, Reagent, Kits, Slide Staining System, Tissue Microarray) Application (Diagnostics (Cancer, Cardiovascular, Diabetes, Autoimmune, Infectious Diseases) & Drug Testing) End User - Global Forecast to 2021
    Published: 29-Nov-2016        Price: US 5650 Onwards        Pages: 225
    The immunohistochemistry (IHC) market is projected to reach USD 2.12 Billion by 2021, growing at a CAGR of 7.3% during the forecast period of 2016 to 2021. Factors such as the growing prevalence of cancer and rapidly increasing geriatric population across the globe are the primary driving the growth of this market. Other factors driving the IHC market growth include increasing healthcare spending and improving healthcare infrastructure resulting in an increasing number of hospitals and diagno......
  • Global Expression Vectors Sales Market Report 2016
    Published: 29-Nov-2016        Price: US 4000 Onwards        Pages: 121
    Notes: Sales, means the sales volume of Expression Vectors Revenue, means the sales value of Expression Vectors This report studies sales (consumption) of Expression Vectors in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Merck - Thermo Fisher Scientific - Agilent Technolo......
  • Global Molecular Biology Kits Sales Market Report 2016
    Published: 29-Nov-2016        Price: US 4000 Onwards        Pages: 123
    Notes: Sales, means the sales volume of Molecular Biology Kits Revenue, means the sales value of Molecular Biology Kits This report studies sales (consumption) of Molecular Biology Kits in Global market, especially in USA, China, Europe, Japan, India and Southeast Asia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - QIAGEN - Agilent Technologies - Merck......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs